Vireo Growth (VREOF) Cash from Investing Activities (2020 - 2026)

Vireo Growth (VREOF) reported Cash from Investing Activities of $8.0 million for Q1 2026, up 827.27% on a YoY basis from $862745.1 in Q1 2025, and up 184.91% sequentially from -$9.4 million in Q4 2025.

Vireo Growth (VREOF) Cash from Investing Activities (2020 - 2026) Analysis & Trends

Vireo Growth (VREOF) has 7 years of Cash from Investing Activities data on file, last reported at $8.0 million in Q1 2026.

  • For the quarter ending Q1 2026, Cash from Investing Activities rose 827.27% year-over-year to $8.0 million; the trailing twelve-month figure through Mar 2026 stood at $17.9 million (up 318.25% YoY), and the FY2025 full-year result was $8.8 million, up 207.71% from the prior year.
  • Cash from Investing Activities improved to $8.0 million in Q1 2026, from -$9.4 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $34.0 million in Q2 2025 to a low of -$14.8 million in Q3 2025.
  • A 5-year average of -$27337.1 and a median of -$1.1 million in 2023 frame the typical range for Cash from Investing Activities.
  • Across the five-year window, Cash from Investing Activities sank 1423.26% in 2024 and soared 1167.2% in 2025, its largest moves.
  • Tracing VREOF's Cash from Investing Activities over 5 years: stood at -$819539.0 in 2022, then jumped by 79.11% to -$171183.0 in 2023, then slumped by 1423.26% to -$2.6 million in 2024, then tumbled by 261.33% to -$9.4 million in 2025, then soared by 184.91% to $8.0 million in 2026.
  • Business Quant data shows VREOF's Cash from Investing Activities at $8.0 million in Q1 2026, -$9.4 million in Q4 2025, and -$14.8 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Haleon 90.13 Bn 88.27 Bn - -
2 Teva Pharmaceutical Industries 35.98 Bn 32.24 Bn 1.97 Bn 229.00 Mn
3 Zoetis 32.59 Bn 30.65 Bn 1.62 Bn -87.00 Mn
4 Takeda Pharmaceutical 27.55 Bn 23.49 Bn 4.39 Bn -369.95 Mn
5 United Therapeutics 23.08 Bn 20.93 Bn 648.10 Mn 743.70 Mn
6 RedHill Biopharma 21.48 Bn 21.48 Bn - -
7 Viatris 20.38 Bn 18.57 Bn 1.16 Bn 277.40 Mn
8 Neurocrine Biosciences 17.80 Bn 16.48 Bn 800.70 Mn -506.20 Mn
9 Elanco Animal Health 12.64 Bn 12.21 Bn 785.00 Mn -60.00 Mn
10 Vireo Growth 10.51 Bn 10.36 Bn 59.30 Mn 8.00 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 8.00 Mn
Mar 31, 2026 8.00 Mn
Dec 31, 2025 -9.42 Mn
Dec 31, 2025 -9.42 Mn
Sep 30, 2025 -14.76 Mn
Sep 30, 2025 -14.76 Mn
Jun 30, 2025 34.04 Mn
Jun 30, 2025 34.04 Mn
Mar 31, 2025 -1.10 Mn
Mar 31, 2025 -1.10 Mn
Dec 31, 2024 -2.61 Mn
Dec 31, 2024 -2.61 Mn
Sep 30, 2024 -1.29 Mn
Sep 30, 2024 -1.29 Mn
Jun 30, 2024 -3.19 Mn
Jun 30, 2024 -3.19 Mn
Mar 31, 2024 -1.05 Mn
Mar 31, 2024 -1.05 Mn
Dec 31, 2023 -171,183.00
Dec 31, 2023 -171,183.00